Design-Efficiency in Security

In this document, we present our applied results on balancing security and performance using a running example, which is based on sensor networks. These results are forming a basis for a new approach to balance security and performance, and therefore provide design-efficiency of key updates. We employ probabilistic model checking approach and present our modelling and analysis study using PRISM model checker

Pyomyositis of tensor fascia lata: a case report

<p>Abstract</p> <p>Introduction</p> <p>Pyomyositis is a disease in which an abscess is formed deep within large striated muscles.</p> <p>Case presentation</p> <p>We report the case of a 10-year-old boy who presented with fever and a painful hip and was subsequently diagnosed with pyomyositis of the tensor fascia lata. In children with clinical and laboratory findings of inflammation in the vicinity of the hip joint, the differential diagnosis includes transient synovitis, an early stage of Legg-Calvé-Perthes disease, infectious arthritis of the hip, rheumatologic diseases and extracapsular infection such as osteomyelitis.</p> <p>Conclusion</p> <p>To the best of the authors' knowledge, this is the first report of pyomyositis of the tensor fascia lata. Although pyomyositis is a rare disease and the differential diagnosis includes a variety of other commonly observed diseases, pyomyositis should be considered in cases where children present with fever, leukocytosis and localized pain.</p

Mutations in Influenza A Virus (H5N1) and Possible Limited Spread, Turkey, 2006

We report mutations in influenza A virus (H5N1) strains associated with 2 outbreaks in Turkey. Four novel amino acid changes (Q447L, N556K, and R46K in RNA polymerase and S133A in hemagglutinin) were detected in virus isolates from 2 siblings who died

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p&lt;0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p&lt;0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark

Summary

The IEEE 802.16e-2005 specification provides an air interface standard for metropolitan area wireless broadband service. IEEE 802.16 is the basis for Worldwide Interoperability for Microwave Access (WiMAX) certification which is the next evolution in wireless technology. The latest version of the standard, the IEEE 802.16e addresses mobility and also enhances the security sublayer of the IEEE 802.16 standard. Since wireless technology is broadcast and transmitted data can be intercepted, wireless users face more risks than wired users. The former IEEE 802.16 standards used the Privacy and Key Management (PKM) protocol which had many critical drawbacks. In IEEE 802.16e, a new version of this protocol called PKMv2 is released. PKMv2 has radical changes and in contrast with the previous version it seems to have an exaggerated mixture of security features like nonces, message authentication codes, key ids, certificates, etc. The PKMv2 includes two main issues: an Authentication/Authorization protocol to establish a shared Authorization Key (AK), and a 3-Wa